Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
Wellcome Trust: Mind the Funding Gap
Dr Georgios Trichas
About us Global independent charitable foundation dedicated to achieving extraordinary improvements in health by supporting the brightest minds.
Our History
The Wellcome Trust was set up in 1936 under the will of Sir Henry Wellcome, who vested the entire share of his pharmaceutical company, The Wellcome Foundation (sold in 1995), in a charitable trust.
Endowment in 1936 - $124,000
• Endowment of $25bn
• Sponsor of >5000 researchers globally
• 60 years of continuous support for research
• Spend ~$1.2 billion per year
• Translational Funding ~$136m
Today
Organization
Science
Innovations Translational
Hypothesis Driven
Culture & Society History & Education
Investments Capital growth of endowment
Equity & Equity Long/Short Absolute Return & Buyout Healthcare & Venture Property & Infrastructure Private Equity
Evergreen Fund
Bridge the gap between fundamental research and commercial application.
Fund applied research and development projects to a stage where they are attractive to a follow-on funder, such as venture capital firms, industry and public-private partnerships.
Driven by unmet medical need
Innovations: Our Purpose
Translational funding to date
Input 303 projects supported Range: £25K - £11.2M £534 million committed
Output £1.19billion leveraged
32 exits via M&A/listing or licensing, 15 products launched
0
10
20
30
40
50
60
70
80
90
100
02/03 03/04 04/05 05/06 06/07 07/08 08/09 09/10 10/11 11/12 12/13
GB
P (£
) Mill
ions
Funding Year
Award Commitments GBP £m
Translation FundInnovative engPathfindersHealth InnovIndia H'careMed EngSDDSACsSTATA
£1.8m£7.5m
£15m £15.8m
£37.5m
£57.1m
£81.5m£73.3m
£61.5m
£83.2m£88.6m
Diagnostics11%
Enabling Technology14%
Medical Devices23%
Regenerative Medicine
4%
Therapeutics40%
Vaccines8%
Therapeutic Areas funded
Technology Types funded
Funding Programmes Available
R&D for Affordable Healthcare in India
Seeding Drug Discovery
Translation Fund Pathfinders
• Facilitate early-stage small-molecule drug discovery • Starting points - novel drug target or new chemistry • Global eligibility, 2 calls per year, triage committee
then full committee • Two entry points to the scheme
• ‘Early stage’ projects fund screening to identify lead series molecules - up to 2y, £1-2m
• ‘Late stage’ projects to support lead optimisation and preclinical development to clinical trials - up to 4y, £3-5m
• Next deadline 5th November 2014
Seeding Drug Discovery
Target Discovery
Lead Optimisation Hit to lead
Assay Development
Pre-clinical Evaluation IND filing
years 3-6 month 6-12 month 12-24 month 12 month Development (years)
“To develop drug-like, small molecules that will be the springboard for further R & D by the industry in areas of
unmet medical need”
Early Late
Seeding Drug Discovery
• To develop innovative and ground-breaking new technologies in the biomedical area
• Already demonstrated proof of principle • Across types of technology and therapeutic areas • Global eligibility - two rounds per year • Normally £0.5m - £5m over 2-4y • Apply by concept note, preliminary applications by
invitation only • Next deadline 24th October 2014
Translation Fund
Funding Model: Not-for-profit organisations
• Funding is based on the Trust’s Standard Funding agreement template (available on website)
• Project revenue is normally split 50:50 between organisation and Trust
• Funding only covers project related cost (no overhead costs)
• Funding is tranched and milestone dependent • Tranches released on successful completion of a
Milestone (Go/No Go Decision Point)
The fine(r) print • For the SDD programme, the Trust normally expects
to be responsible for commercialisation of the Project IP
• Where the organisation is responsible for exploitation of Project IP, the Trust expects to have step-in rights
• The Trust will exert project oversight through participation in Research Steering Group meetings
• Project IP is owned by the organisation
• While the Trust supports dissemination of results all publications must be approved by the Intellectual Project Management Group
Wellcome Trust: Mind The Funding Gap
The Application Process
Triage Committee
Staff Committee
Concept Note (Translation Fund Only)
Preliminary Application
Full Application
Funding Committee presentation
Expert Reviews & Due Diligence
The Seven Deadly Sins
I. Weak scientific rational (target validation)
II. Healthcare impact limited / unrealistic competitive advantage
III. Major practical implementation hurdle
IV. Major chemical hurdle / low probability of success
V. Lack of key expertise VI. Poor project plan / under-
resourced VII. Unrealistic ‘exit’ / Target Product
Profile
Some awardees